Treatment for Gonococcal Conjunctivitis
For adults with gonococcal conjunctivitis, treat with ceftriaxone 1 g intramuscularly (IM) as a single dose PLUS concurrent treatment for chlamydia with either azithromycin 1 g orally as a single dose OR doxycycline 100 mg orally twice daily for 7 days. 1
Treatment Algorithm by Patient Population
Adults (≥18 years)
- Primary regimen: Ceftriaxone 1 g IM single dose
- PLUS mandatory co-treatment for chlamydia:
- Azithromycin 1 g PO single dose, OR
- Doxycycline 100 mg PO twice daily × 7 days 1
Rationale: The CDC mandates concurrent chlamydia treatment because 40-50% of patients with gonococcal infections are co-infected with Chlamydia trachomatis 1. This dual therapy approach prevents treatment failure and addresses both pathogens simultaneously.
Pregnant Patients
- Gonococcal treatment: Ceftriaxone 1 g IM single dose
- Chlamydia co-treatment: Azithromycin 1 g PO single dose OR Amoxicillin 500 mg PO three times daily × 7 days
- AVOID: Doxycycline, quinolones, and tetracyclines 1
Children and Adolescents
Children weighing ≤45 kg:
- Ceftriaxone 25-50 mg/kg IM/IV single dose (maximum 250 mg) 1
Children weighing >45 kg:
- Same treatment as adults 1
Plus chlamydia coverage based on age:
- <45 kg: Erythromycin 50 mg/kg/day divided into 4 doses × 14 days
- ≥45 kg but <8 years: Azithromycin 1 g PO single dose
- ≥8 years: Azithromycin 1 g PO single dose OR Doxycycline 100 mg PO twice daily × 7 days 1
Neonates (Ophthalmia Neonatorum)
- Ceftriaxone 25-50 mg/kg IV or IM single dose (maximum 250 mg) 1, 2
- Critical: Hospitalize and evaluate for disseminated infection (sepsis, arthritis, meningitis) 2
- Topical antibiotics are inadequate and unnecessary if systemic treatment is given 2
Key Clinical Considerations
Alternative Regimens (When Ceftriaxone Unavailable)
If ceftriaxone is not available, consider:
- Cefixime 400 mg PO single dose, OR
- Doxycycline 100 mg PO twice daily × 7 days
- Plus saline lavage of infected eye 1
Severe Cephalosporin Allergy
Azithromycin 2 g PO single dose is effective but NOT recommended for widespread use due to emerging macrolide resistance. Consult infectious disease specialists for patients with severe cephalosporin allergy 1. This is a critical pitfall—do not routinely substitute azithromycin without specialist input.
Adjunctive Measures
- Consider single saline lavage of the infected eye 1
- Topical antibiotics alone are inadequate and unnecessary with systemic therapy 2
Critical Management Pitfalls to Avoid
Never treat gonococcal conjunctivitis with topical antibiotics alone—this is inadequate and risks corneal perforation and blindness 2
Always co-treat for chlamydia—failure to do so results in persistent infection in 40-50% of cases 1
Hospitalize neonates—they require evaluation for disseminated infection and close monitoring 2
Use caution with ceftriaxone in hyperbilirubinemic infants, especially premature neonates 2
Document sexual abuse concerns in prepubertal children—gonococcal conjunctivitis in this age group is highly concerning for sexual contact and warrants protective agency reporting 3
Follow-Up and Partner Management
Retest at 3 months: All patients with gonococcal or chlamydial infection should be retested approximately 3 months after treatment 1
Sexual partner notification: All sexual partners must be evaluated and treated. Refer patients to sexual health services for comprehensive STI screening and contact tracing 4. In one series, 57% of patients had concurrent STIs identified or treatments changed following sexual health review 4
Test of cure: While not routinely required, if performed, all cultures were negative when checked 10-79 days post-treatment 5
Evidence Quality Note
The 2024 Ophthalmology Conjunctivitis Preferred Practice Pattern guidelines 1 are based on 2021 CDC STD Treatment Guidelines and represent the most current, authoritative recommendations. These supersede older 2006 CDC guidelines 2. The treatment approach has remained consistent with ceftriaxone as first-line therapy, with the critical addition of mandatory chlamydia co-treatment. Recent case series 6, 5, 4 confirm excellent outcomes with this regimen, with no corneal perforations when treatment is initiated promptly.